Role of Betahistine in the Management of Vertigo

Abstract

Though betahistine is the most commonly prescribed drug for vertigo, there are a lot of controversies on its efficacy as well as its proclaimed mechanism of action. There are authentic studies that have shown it to be no different from a placebo in Ménière’s disease. It is often promoted as a vestibular stimulant, but scientific evidence suggests that it is a vestibular suppressant. It is also not very clear whether it is an H₃-receptor antagonist as most promotional literature shows it to be, or whether it is an inverse agonist of the H3 receptors. Owing to insufficient data on its efficacy in Ménière’s disease, betahistine is not approved by the U.S. Food and Drug Administration (FDA). The much-advertised role of betahistine in augmenting histaminergic transmission and thereby inducing arousal, though beneficial is some ways in the restoration of balance after peripheral vestibulopathy, is yet not without systemic problems, and the pros and cons of histaminergic stimulation in the brain need to be assessed more by clinical studies in humans before imbibing it in clinical practice. The effect of increasing blood flow to the cochlea and the vestibular labyrinth and “rebalancing the vestibular nuclei” (as claimed in some literature) and whether they are actually beneficial to the patient with vertigo in the therapeutic doses are very controversial issues. The mechanism of action of betahistine in vertigo in general and in Ménière’s disease in particular is very confusing, and there are too many conjectural and hypothetical, if not controversial issues involved that call for close scrutiny. Everything taken together, betahistine appears to be an unduly hyped-up drug and clinicians need to review the scientific literature available and be convinced about its efficacy and mechanism of action before using it in clinical practice. This review article puts forth some controversial issues and reviews the relevant scientific literature for clinicians to analyze and then take the final call on its clinical use.

Keywords

betahistine - treatment of vertigo - H₃-receptor - treatment of Ménière’s disease - betahistine in Ménière’s disease

• References

• 1 Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M. BEMED Study Group. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016; 352: h6816
• 2 Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001; 15 (11) 853-870
• 3 Lacour M. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J Vestib Res 2013; 23 (03) 139-151
• 4 Hain TC. Serc (Betahistine). Available at: https://www.dizziness-and-balance.com/treatment/drug/serc.html. Accessed October 13, 2018
• 5 Hain TC, Uddin M. Pharmacological treatment of vertigo. CNS Drugs 2003; 17 (02) 85-100
• 6 James AL, Burton MJ. Betahistine for Menière’s disease or syndrome. Cochrane Database Syst Rev 2001; (01) CD001873
• 7 Sampson WI. Homeopathic vs conventional treatment of vertigo. Arch Otolaryngol Head Neck Surg 2003; 129 (04) 497 author reply 498
• 8 Botta L, Mira E, Valli S. et al. Effects of betahistine and of its metabolites on vestibular sensory organs. Acta Otorhinolaryngol Ital 2001; 21 (03) Suppl 66 24-30
• 9 Gbahou F, Davenas E, Morisset S, Arrang JM. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. J Pharmacol Exp Ther 2010; 334 (03) 945-954
• 10 Timmerman H. Pharmacotherapy of vertigo: any news to be expected?. Acta Otolaryngol Suppl 1994; 513: 28-32
• 11 Tighilet B, Leonard J, Lacour M. Betahistine dihydrochloride treatment facilitates vestibular compensation in the cat. J Vestib Res 1995; 5 (01) 53-66
• 12 Serafin M, Khateb A, Vibert N, Vidal PP, Mühlethaler M. Medial vestibular nucleus in the guinea-pig: histaminergic receptors. I. An in vitro study. Exp Brain Res 1993; 93 (02) 242-248
• 13 Takeda N, Morita M, Kubo T, et al. Histaminergic projection from the posterior hypothalamus to the medial vestibular nucleus of rats and its relation to motion sickness. In: Graham MD, Kemink JL, eds. The Vestibular System: Neurophysiologic and Clinical Research. New York, NY: Raven Press; 1987:571–580
• 14 Jaju BP, Wang SC. Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther 1971; 176 (03) 718-724
• 15 Kirsten EB, Sharma JN. Microiontophoresis of acetylcholine, histamine and their antagonists on neurones in the medial and lateral vestibular nuclei of the cat. Neuropharmacology 1976; 15 (12) 743-753
• 16 Passani MB, Panula P, Lin JS. Histamine in the brain. Front Syst Neurosci 2014;8:64
• 17 Torrealba F, Riveros ME, Contreras M, Valdes JL. Histamine and motivation. Front Syst Neurosci 2012; 6: 51
• 18 Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series. Eur Arch Otorhinolaryngol 2011; 268 (08) 1237-1240
• 19 Redon C, Lopez C, Bernard-Demanze L. et al. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol 2011; 51 (04) 538-548
• 20 Ramos Alcocer R, Ledezma Rodríguez JG, Navas Romero A. et al. Use of betahistine in the treatment of peripheral vertigo. Acta Otolaryngol 2015; 135 (12) 1205-1211